Does anesthesia choice shape oncologic destiny in gastric cancer surgery?

Table 1 Summary of preclinical and clinical studies investigating the antitumor and immunomodulatory effects of propofol in gastric cancer

Ref.	Key findings	Method
Ni et al[11]	Suppresses cell invasion via MMP-2 inhibition through miR-29	In vitro
Liu et al[12]	Inhibits tumor growth via the circPDSS1/miR-1324/SOX4 axis	In vitro
Xian et al[15]	Reduces proliferation through YAP1 inhibition mediated by miR-205	In vitro
Zhan et al[16]	Inhibits tumor progression through the miR-493-3p/DKK1/Wnt-β-catenin axis	In vitro
Zhang et al[17]	Increases cisplatin sensitivity via lncRNA MALAT1/miR-30e/ATG5 pathway	In vitro + chemotherapy sensitivity
Ai et al[19]	Enhances antitumor immunity by increasing NK cell activity	Clinical study
Zheng et al[18]	Propofol-TIVA associated with better postoperative outcomes	Retrospective clinical
Liu and Yang[29]	Provides more stable glucose and cytokine profiles (in diabetic patients)	Clinical study
Li et al[27]	Observed improved neurocognitive recovery	Clinical study
Cao et al[14]	Suppresses tumor proliferation via NRF2	In vitro

NK: Natural killer; TIVA: Total intravenous anesthesia.